National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers

This publication has 15 references indexed in Scilit:

• Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States I. Study on the threat of emerging resistances: Real or perceived?
  Diagnostic Microbiology and Infectious Disease, 1994
• Piperacillin/Tazobactam
  Drugs, 1994
• Behaviour of β-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other β-lactam/β-lactamase inhibitor combinations
  Journal of Antimicrobial Chemotherapy, 1993
• Increasing problems in the therapy of enterococcal infections
  European Journal of Clinical Microbiology & Infectious Diseases, 1993
• Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections
  Journal of Antimicrobial Chemotherapy, 1993
• Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections
  Antimicrobial Agents and Chemotherapy, 1992
• Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I β-lactamases
  Journal of Antimicrobial Chemotherapy, 1990
• Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830)
  Diagnostic Microbiology and Infectious Disease, 1989
• Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam
  Antimicrobial Agents and Chemotherapy, 1989
• Synthesis and .beta.-lactamase inhibitory properties of 2.beta.-[(1,2,3-triazol-1-yl)methyl]-2.alpha.-methylpenam-3.alpha.-carboxylic acid 1,1-dioxide and related triazolyl derivatives
  Journal of Medicinal Chemistry, 1987